Several years of research, supported by our investors

LATTICE MEDICAL, created at the end of 2017, makes the most of several years of research by Lille University Hospital and the University of Lille in tissue engineering for the regeneration of autologous adipose tissue. The company operates a patented technology that has been extended internationally, with its first application in breast reconstruction.

Betting on the reconstructive surgery of tomorrow

LATTICE MEDICAL aims to revolutionise breast reconstruction with its MATTISSE implant, enabling autologous reconstruction for all patients and becoming the market leader in human soft tissue repair. Our ambition is to replace silicone implants and help 40,000 women by 2030 to have simpler, risk-free breast reconstruction.

Becoming an investor

Join the adventure
become an investor

The current global market for breast reconstruction is estimated at €1.2 billion in 2019, growing by 5% a year to reach €1.8 billion in 2027. In parallel, the market for cosmetic breast surgery is estimated at €1.7 billion in 2020. The three growth markets are the United States, the world’s largest market, Europe and Brazil, which together account for a market worth €900 million. LATTICE MEDICAL is targeting 5% of this market by 2030.

Become an investor

Next steps in the
development of Lattice Medical

The roadmap has already been written for the coming years. Here's a glimpse of what we're planning for the future.

First fund-raising of €2.3 million.
Validation of the design and production process of our MATTISSE implants.
Second fund-raising round of €8 million.
Start of clinical trials for our MATTISSE device

A year ago, we began clinical trials on our MATTISSE breast prosthesis.

Publication of the interim clinical report on the TIDE study

Communication of our first clinical results on 10 patients with 6 to 12 months of follow-up, both on safety data and on the performance of the MATTISSE implant.

End of inclusion in the TIDE study

End of inclusion of the last patient and finalisation of our technical file with a view to CE marking

ISO 13485:2016 marking for Class III medical devices

Passing of the audit with our notified body for the validation of our quality system for the design, development and manufacture of breast implants.

Launch of clinical investigation USA

Launch of clinical investigation in the USA with a view to FDA approval.

Start of clinical investigation for RODIN

Launch of the European pre-market clinical investigation for our product RODIN.

MATTISSE is CE marked and goes on sale in Europe.
RODIN CE mark and start of sales in Europe.

Any questions?

We will be delighted to answer your questions.